Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix™ vaccine in pregnant women

Trial Identifier: 116945
Sponsor: GlaxoSmithKline
NCTID:: NCT02377349
Start Date: October 2015
Primary Completion Date: August 2017

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, Victoria Carlton, Victoria, Australia, 3053
Australia, Victoria Fitzroy, Victoria, Australia, 3065
Australia, Victoria Parkville, Victoria, Australia, 3052
Canada, Alberta Calgary, Alberta, Canada, T3B 6A8
Canada, Nova Scotia Halifax, Nova Scotia, Canada, B3K 6R8
Canada, Ontario Sudbury, Ontario, Canada, P3A 1W8
Canada, Québec Montreal, Québec, Canada, H3T 1C5
Canada, Québec Mount Royal, Québec, Canada, H3P 3W3
Czech Republic Brno, Czech Republic, 613 00
Czech Republic Hradec Kralove, Czech Republic, 500 02
Czech Republic Ostrava - Vitkovice, Czech Republic, 703 84
Czech Republic Praha, Czech Republic, 14700
Czech Republic Praha 4, Czech Republic, 14059
Finland Kokkola, Finland, 67100
Finland Oulu, Finland, 90220
Finland Seinajoki, Finland, 60100
Finland Tampere, Finland, 33100
Finland Turku, Finland, 20520
Italy, Lombardia Milano, Lombardia, Italy, 20154
Italy, Lombardia Milano, Lombardia, Italy, 20142
Italy, Lombardia Milano, Lombardia, Italy, 20122
Italy, Piemonte Novara, Piemonte, Italy, 28100
Italy, Piemonte Torino, Piemonte, Italy, 10126
Spain Antequera/Málaga, Spain, 29200
Spain Aravaca, Spain, 28023
Spain Boadilla del Monte, Spain, 28660
Spain Burgos, Spain, 09006
Spain Madrid, Spain, 28046
Spain Madrid, Spain, 28040
Spain Majadahonda (Madrid), Spain, 28222
Spain Móstoles, Spain, 28938
Spain Santiago de Compostela, Spain, 15706
Spain Sevilla, Spain, 41940
Spain Sevilla, Spain, 41013
Spain, Andalucia Malaga, Andalucia, Spain, 29004